Japanese Symposium on Tragic HPV Vaccine
Behind The Scenes of The Japanese Symposium on The Tragic HPV Vaccine Outcomes
Posted Thursday, May 30, 2019 at 07:02pm EDT
If Japan can have a public and honest debate about vaccines, why can’t we have that same debate here in Australia?
The Japanese Ministry of Health secretly planned a visit to London for sometime in October 2013 to have discussions on the HPV vaccines with officials in the UK Department of Health and the Medicines and Healthcare Products Regulatory Agency (MHRA). This delegation also wanted to speak with scientific and medical experts who were independent of pharmaceutical industry conflicts of interest.
A one Mr. Tetsuya Miyamoto, Director of the Office of Vaccination Policy at the Ministry of Health led that secret mission to get ALL the information about the HPV vaccine.
There had been a spate of very nasty HPV vaccine adverse reactions in Japanese girls and their government was determined to find out if the vaccine was in fact harming those girls.
The Japanese symposium and debate was organized in a very short time frame on behalf of ‘The Researchers Organization Sounding a Warning concerning the Adverse Reactions induced by Human Papillomavirus Vaccines’ through the collaborative efforts of Dr. Harumi Sakai, former Professor at the Tokai University School of Medicine, Dr. Shohei Matsuzaki, Professor Emeritus at the Tokai University School of Medicine, Mutsuo Fukushima, Kyoto News International Department, and SaneVax Inc.
Professor Authier was one of the medical experts that the Japanese delegation spoke to. He consequently testified at the Japanese HPV public hearing, the meeting with the Japanese Senators and at news conferences. The following is his conclusion at the end of his testimony research paper titled, ‘Macrophagic myofasciitis New insights on the long-term safety of aluminum adjuvants’ …
“Neuromigration of alum particles is an active process’
- Alum particles can be transported by monocyte-lineage cells to lymph nodes, blood and spleen, and, similarly to HIV, may use MCP1/CCL2- dependent mechanisms to penetrate the brain. This occurs at a very low rate in normal conditions explaining good overall tolerance of alum despite its strong neurotoxic potential.- However, continuously escalating doses of the poorly biodegradable alum adjuvant in the population may become insidiously unsafe, especially in case of overimmunization
- or immature/altered blood brain barrier
- or high constitutive CCL-2 production.”
Authier is also a co-author of a research paper that states, “Nanomaterials can be transported by monocyte-lineage cells to DLNs, blood and spleen, and, similarly to HIV, may use CCL2-dependent mechanisms to penetrate the brain. This occurs at a very low rate in normal conditions explaining good overall tolerance of alum despite its strong neurotoxic potential. However, continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe, especially in the case of overimmunization or immature/altered blood brain barrier or high constitutive CCL-2 production”
‘Macrophagic myofasciitis New insights on the long-term safety of aluminum adjuvants’ http://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000038475.pdf (as accessed 30 June 2018).REF – ‘Slow CCL2-dependent translocation of biopersistent particles from muscle to brain’ https://www.ncbi.nlm.nih.gov/pubmed/?term=23557144
‘Slow CCL2-dependent translocation of biopersistent particles from muscle to brain’ BMC Medicine 201311:99 https://doi.org/10.1186/1741-7015-11-99 (as accessed 16 May 2019).